Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd63/MVA ME-TRAP Malaria Vaccine Efficacy Study
NCT01666925Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Mar 2012
- Primary completion
- Aug 2012
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ChAd63 ME-TRAP and MVA ME-TRAP in Plasmodium falciparum malaria (2 arms), sponsored by University of Oxford. Primary endpoint: Vaccine Efficacy at 18 weeks. Started Mar 2012; status: completed.
02
Drugs
ChAd63 ME-TRAPMVA ME-TRAP
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT01666925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01666925.